DOTW Takes A Look At Stock Movements
In the hum-drum days of August, deals have been sparse, but a spate of bad clinical trial results in recent weeks shows how risky pharma R&D is. The news -- around J&J/Pfizer/Elan's Alzheimer's disease monoclonal antibody bapineuzumab, Merck'..
Original Article: DOTW Takes A Look At Stock Movements
NEXT ARTICLE